joris

Triage board

Triage means a quick first look at many programs to decide which ones deserve a full analysis. This one board lists every program that has passed a triage screen. Each program appears once, identified by its BPIQ drug id (BPIQ is the biotech data service we use). If a program is screened again, its row is updated, not duplicated. The most recent screen wins. This is the start of the process: the next full analysis is picked from here.

Latest screen 2026-08-11 · 3 screening run(s) saved

NOT CITABLE: for screening only

This board is a quick, low-cost ranking. It is not an analysis. Do not use any claim from this board in a program analysis unless it is checked again there (framework/02-connectors.md § Triage pass). The board is only for deciding what to analyse next. It does not support a claim by itself.

On the board

140

still current

Screened

130

not yet decided

Shortlisted

0

waiting for a full analysis

Analysed

10

full analysis done

Dismissed

0

ruled out

Candidates

Sorted by catalyst date (the date of the big event), earliest first, then by tier (A is best)

State
Tier
State Candidate Catalyst Signals Flags Actions
Analysed
A

IMMP

Eftilagimod alpha + pembrolizumab

Soft tissue sarcoma (EFTISARC-NEO)

October 19, 2026

exact day given

0 delays

N/A $58M market cap
in no hfs
Screened
A

EVAX

EVX-01 + pembrolizumab

Melanoma

October 24, 2026

exact day given

0 delays

N/A $25M market cap
—
Analysed
B

CMPX

Tovecimig (CTX-009)

Biliary tract cancer (COMPANION-002)

October 24, 2026

exact day given

5 delays

OK $343M market cap
in top10 hfs
Screened
C

AGEN

Botensilimab/Balstilimab (BOT/BAL)

Neoadjuvant dMMR colorectal cancer

October 25, 2026

exact day given

0 delays

EXPIRED $312M market cap
in no hfs
Analysed
B

RAPP

RAP-219

Bipolar mania

October 2026

only the month given

1 delay

OK $2.03B market cap
high mgmt interest
Screened
C

GUTS

Revita (DMR)

Obesity / T2D (REMAIN-1 pivotal 6-month)

Early Q4 2026

rough period (placeholder)

1 delay

TIGHT $109M market cap
high mgmt interest
Analysed
A

OLMA

Palazestrant (OP-1250)

ER+/HER2- metastatic breast cancer (OPERA-01)

Fall 2026

only the month given

2 delays

OK $1B market cap
big mover high mgmt interest
Screened
A

PEPG

PGN-EDODM1

Myotonic dystrophy type 1 (FREEDOM2, 10mg MAD)

November 2026

only the month given

2 delays

OK $137M market cap
high mgmt interest
Analysed
A

IMUX

Vidofludimus calcium (IMU-838)

Relapsing MS (ENSURE-1/-2)

YE 2026

rough period (placeholder)

0 delays

OK $190M market cap
high mgmt interest
Analysed
A

IVA

Lanifibranor (pan-PPAR)

MASH (NATiV3)

H2 2026

rough period (placeholder)

1 delay

N/A $1.06B market cap
suspected mover hedge fund pick high mgmt interest in top10 hfs
Screened
A

RZLT

Ersodetug

Tumor hyperinsulinism (upLIFT)

H2 2026

rough period (placeholder)

0 delays

OK $454M market cap
big mover
Screened
A

IMTX

ACTengine IMA203 GEN1 (PRAME)

Cutaneous melanoma (SUPRAME)

2026

rough period (placeholder)

0 delays

OK $1.18B market cap
suspected mover high mgmt interest
Screened
A

ANNX

Vonaprument (ANX007, IVT)

Geographic atrophy (ARCHER II)

H2 2026

rough period (placeholder)

1 delay

OK $834M market cap
high mgmt interest
Screened
A

VIR

Tobevibart + elebsiran

Hepatitis delta (ECLIPSE 1)

Q4 2026

rough period (placeholder)

1 delay

OK $1.46B market cap
suspected mover high mgmt interest
Screened
A

CRVS

Soquelitinib (CPI-818)

Peripheral T-cell lymphoma (interim)

Late 2026

rough period (placeholder)

1 delay

OK $1.12B market cap
in top10 hfs
Screened
A

TARA

IV choline chloride

Intestinal-failure-associated liver disease (THRIVE-3 interim)

H2 2026

rough period (placeholder)

0 delays

OK $220M market cap
—
Screened
A

SLGL

SGT-610 (patidegib)

Gorlin syndrome

Q4 2026

rough period (placeholder)

0 delays

N/A $268M market cap
—
Screened
A

MNOV

MN-166 (ibudilast)

ALS (COMBAT-ALS)

YE 2026

rough period (placeholder)

0 delays

OK $65M market cap
—
Screened
A

DMAC

DM199 (rinvecalinase alfa)

Acute ischemic stroke (ReMEDy2 interim)

H2 2026

rough period (placeholder)

0 delays

OK $341M market cap
suspected mover hedge fund avoid high mgmt interest
Analysed
A

GNLX

Olvi-Vec + platinum doublet + bevacizumab

Platinum-resistant ovarian cancer (OnPrime/GOG-3076)

H2 2026

rough period (placeholder)

1 delay

OK $131M market cap
high mgmt interest
Screened
A

VTVT

Cadisegliatin (TTP399)

Type 1 diabetes (CATT1)

H2 2026

rough period (placeholder)

0 delays

N/A $127M market cap
high mgmt interest
Screened
A

AGMB

Ontunisertib (AGMB-129)

Fibrostenosing Crohn's disease

H2 2026

rough period (placeholder)

0 delays

OK $705M market cap
—
Screened
A

BMEA

BMF-219 (icovamenib) + GLP-1

Severe insulin-deficient T2D (COVALENT-211)

Q4 2026

rough period (placeholder)

0 delays

OK $90M market cap
high mgmt interest
Screened
A

CLYM

Budoprutug

Primary membranous nephropathy (PrisMN)

Q4 2026

rough period (placeholder)

0 delays

OK $714M market cap
big mover hedge fund avoid in no hfs
Screened
A

ENGN

Detalimogene (EG-70)

Non-muscle invasive bladder cancer (LEGEND)

H2 2026

rough period (placeholder)

0 delays

OK $121M market cap
high mgmt interest in top10 hfs
Screened
A

GNLX

Olvi-Vec

Small cell lung cancer (China, systemic)

2026

rough period (placeholder)

0 delays

OK $113M market cap
in no hfs
Screened
A

GNLX

Olvi-Vec

NSCLC (VIRO-25, systemic)

2026

rough period (placeholder)

0 delays

OK $113M market cap
in no hfs
Screened
A

INKT

AgenT-797 +/- pembrolizumab/nivolumab

Relapsed/refractory solid tumors

2026

rough period (placeholder)

0 delays

OK $58M market cap
in no hfs
Screened
A

INKT

AgenT-797

Acute respiratory disease syndrome / ARDS

H2 2026

rough period (placeholder)

0 delays

OK $58M market cap
high mgmt interest in no hfs
Screened
A

KYTX

KYV-101

Rheumatoid arthritis (IIT)

2026

rough period (placeholder)

0 delays

OK $464M market cap
—
Screened
A

MAZE

MZE829 (APOL1 inhibitor)

APOL1-mediated kidney disease

Q4 2026

rough period (placeholder)

0 delays

OK $1.54B market cap
suspected mover hedge fund pick high mgmt interest in top10 hfs
Screened
A

MNOV

MN-166 (ibudilast)

Chemotherapy-induced peripheral neuropathy (OXTOX)

H2 2026

rough period (placeholder)

0 delays

OK $65M market cap
in no hfs
Screened
A

PCRX

PCRX-201 (enekinragene inzadenovec)

Knee osteoarthritis (ASCEND Part A)

YE 2026

rough period (placeholder)

0 delays

N/A $991M market cap
in no hfs
Screened
A

PHAR

Leniolisib

Immunodeficiency (broader PID)

H2 2026

rough period (placeholder)

1 delay

OK $756M market cap
suspected mover hedge fund avoid in no hfs
Screened
A

QTTB

Bempikibart (ADX-914)

Alopecia areata (Ph2a)

H2 2026

rough period (placeholder)

0 delays

OK $491M market cap
high mgmt interest
Screened
A

SLS

SLS009 (GFH009)

Frontline high-risk AML

Q4 2026

rough period (placeholder)

0 delays

OK $2.33B market cap
in no hfs
Screened
A

SNSE

Piktor (PI3K/mTOR inhibitor)

Advanced endometrial cancer (FTH-PIK-201)

YE 2026

rough period (placeholder)

0 delays

OK $19M market cap
—
Screened
A

TLSA

Intranasal Foralumab

Alzheimer's disease

2026

rough period (placeholder)

0 delays

N/A $126M market cap
in no hfs
Screened
A

ZBIO

Obexelimab

Systemic lupus erythematosus (SunStone)

Q4 2026

rough period (placeholder)

1 delay

OK $1.96B market cap
suspected mover high mgmt interest
Screened
A

ZURA

Tibulizumab

Hidradenitis suppurativa (TibuSHIELD)

Q4 2026

rough period (placeholder)

0 delays

OK $535M market cap
—
Screened
B

IPHA

Monalizumab + durvalumab

NSCLC (PACIFIC-9)

H2 2026

rough period (placeholder)

0 delays

N/A $164M market cap
high mgmt interest
Screened
B

HCM

ORPATHYS (savolitinib) + TAGRISSO

NSCLC (SAFFRON)

H2 2026

rough period (placeholder)

0 delays

N/A $1.93B market cap
suspected mover hedge fund avoid high mgmt interest
Screened
B

IMCR

KIMMTRAK (tebentafusp) +/- anti-PD1

2L+ cutaneous melanoma (TEBE-AM)

2026

rough period (placeholder)

0 delays

OK $1.72B market cap
in top10 hfs
Screened
B

KOD

KSI-101

Macular edema secondary to inflammation (PEAK)

Q4 2026

rough period (placeholder)

0 delays

OK $2.6B market cap
high mgmt interest
Screened
B

IRON

Bitopertin

Erythropoietic protoporphyria (APOLLO)

Q4 2026

rough period (placeholder)

0 delays

OK $2.96B market cap
high mgmt interest in top10 hfs
Screened
B

KPTI

XPOVIO (selinexor) + pomalidomide + dex

Multiple myeloma (XPORT-MM-031)

H2 2026

rough period (placeholder)

0 delays

OK $43M market cap
—
Screened
B

HRMY

WAKIX (pitolisant)

Prader-Willi EDS (TEMPO)

H2 2026

rough period (placeholder)

0 delays

N/A $2.04B market cap
—
Screened
B

PCRX

ZILRETTA (triamcinolone acetonide)

Shoulder osteoarthritis

Q4 2026

rough period (placeholder)

0 delays

N/A $1.04B market cap
suspected mover hedge fund avoid high mgmt interest
Screened
B

VNDA

NEREUS (tradipitant)

GLP-1-induced nausea and vomiting (Thetis)

Q4 2026

rough period (placeholder)

0 delays

OK $306M market cap
—
Screened
B

VNDA

Bysanti (milsaperidone)

Adjunctive major depressive disorder

2026

rough period (placeholder)

0 delays

OK $306M market cap
—
Screened
B

VNDA

VQW-765

Social anxiety disorder

YE 2026

rough period (placeholder)

0 delays

OK $306M market cap
—
Screened
B

XOMA

Ersodetug

Tumor hyperinsulinism (upLIFT)

H2 2026

rough period (placeholder)

0 delays

N/A $710M market cap
suspected mover high mgmt interest
Screened
B

BCYC

Zelenectide pevedotin (BT8009)

Urothelial cancer (Duravelo-2)

H2 2026

rough period (placeholder)

1 delay

OK $269M market cap
—
Screened
B

EIKN

EIK1001

1L advanced melanoma (TeLuRide-006 first interim)

H2 2026

rough period (placeholder)

0 delays

OK $498M market cap
—
Screened
B

EIKN

EIK1001

Stage 4 NSCLC (TeLuRide-008)

H2 2026

rough period (placeholder)

0 delays

OK $498M market cap
—
Screened
B

LYEL

Ronde-cel (LYL314)

Large B-cell lymphoma (PiNACLE)

H2 2026

rough period (placeholder)

0 delays

OK $317M market cap
high mgmt interest
Screened
B

ACIU

ACI-7104.056

Parkinson's disease (VacSYn Part 1)

H2 2026

rough period (placeholder)

1 delay

N/A $233M market cap
big mover high mgmt interest
Screened
B

ADAG

Neoadjuvant Muzastotug (ADG126)

Colorectal cancer (neoadjuvant, IIT)

2026

rough period (placeholder)

0 delays

N/A $279M market cap
in no hfs
Screened
B

ADCT

ZYNLONTA + Rituximab

Follicular lymphoma / MZL (IIT)

YE 2026/Mid-2027

rough period (placeholder)

0 delays

OK $144M market cap
—
Screened
B

ADCT

ZYNLONTA

Marginal zone lymphoma (IIT)

YE 2026/Mid-2027

rough period (placeholder)

0 delays

OK $144M market cap
—
Screened
B

ANAB

Jemperli/Dostarlimab

Locally advanced dMMR/MSI-H rectal cancer (AZUR-1)

H2 2026

rough period (placeholder)

0 delays

OK $1.63B market cap
—
Screened
B

ANAB

Jemperli/Dostarlimab

Stage III MMRp/MSS resectable colon cancer (AZUR-4)

Q4 2026

rough period (placeholder)

0 delays

OK $1.63B market cap
—
Screened
B

BMEA

Icovamenib + GLP-1

Type 2 diabetes (COVALENT-212)

Q4 2026

rough period (placeholder)

0 delays

OK $90M market cap
—
Screened
B

COAG

Sutacimig (HMB-001)

Congenital Factor VII deficiency

Late 2026/Early 2027

rough period (placeholder)

0 delays

OK $2.34B market cap
in no hfs
Screened
B

COYA

COYA 301 (low-dose IL-2)

Alzheimer's disease

H2 2026

rough period (placeholder)

0 delays

OK $107M market cap
—
Screened
B

FGEN

FG-3246 (ADC)

Metastatic castration-resistant prostate cancer

H2 2026

rough period (placeholder)

0 delays

OK $39M market cap
high mgmt interest
Screened
B

FGEN

FG-3180 (CD46 PET tracer)

mCRPC companion diagnostic

H2 2026

rough period (placeholder)

0 delays

OK $39M market cap
—
Screened
B

IFRX

Izicopan

Chronic spontaneous urticaria (Ph2a)

2026

rough period (placeholder)

0 delays

OK $261M market cap
—
Screened
B

IFRX

Izicopan

Hidradenitis suppurativa (Ph2a)

2026

rough period (placeholder)

0 delays

OK $261M market cap
—
Screened
B

IMAB

Uliledlimab (TJD5)

NSCLC (+/- toripalimab, pembrolizumab)

2026

rough period (placeholder)

0 delays

N/A $534M market cap
in no hfs
Screened
B

IOVA

Iovance TIL (LN-145)

NSCLC (2L, IOV-LUN-202)

2026

rough period (placeholder)

0 delays

OK $1.94B market cap
—
Screened
B

KPTI

XPOVIO (selinexor)

Myelofibrosis (SENTRY-2) / ITP

H2 2026

rough period (placeholder)

0 delays

OK $43M market cap
—
Screened
B

KYTX

KYV-101

Myasthenia gravis (KYSA-6)

H2 2026

rough period (placeholder)

0 delays

OK $464M market cap
—
Screened
B

NKTR

Rezpegaldesleukin (NKTR-358)

Alopecia areata (REZOLVE-AA, 24-wk off-treatment)

Q4 2026

rough period (placeholder)

0 delays

OK $2.47B market cap
—
Screened
B

PHAT

VOQUEZNA (vonoprazan)

Eosinophilic esophagitis (pHalcon-EoE-201)

Q4 2026

rough period (placeholder)

0 delays

OK $666M market cap
—
Screened
B

REPL

RP2 + atezolizumab + bevacizumab

Hepatocellular carcinoma

Q4 2026

rough period (placeholder)

0 delays

OK $994M market cap
—
Screened
B

SNDX

Axatilimab (Niktimvo) + ruxolitinib

Newly diagnosed chronic GVHD

Q4 2026

rough period (placeholder)

0 delays

OK $1.78B market cap
suspected mover high mgmt interest
Screened
B

SNDX

Axatilimab

Idiopathic pulmonary fibrosis (MAXPIRe)

Q4 2026

rough period (placeholder)

0 delays

OK $1.78B market cap
—
Screened
B

SPRY

neffy (epinephrine nasal spray)

Acute flares in chronic spontaneous urticaria

Q4 2026

rough period (placeholder)

0 delays

OK $532M market cap
suspected mover high mgmt interest
Screened
B

TNXP

TNX-102 SL (Tonmya)

Acute stress reaction/disorder (OASIS, DoD-funded)

H2 2026

rough period (placeholder)

0 delays

OK $179M market cap
in no hfs
Screened
B

TYRA

TYRA-200

Intrahepatic cholangiocarcinoma

Q4 2026

rough period (placeholder)

0 delays

OK $1.53B market cap
in top10 hfs
Screened
B

XNCR

XmAb942

Inflammatory bowel disease (XENITH-UC interim)

YE 2026

rough period (placeholder)

0 delays

OK $1.47B market cap
suspected mover hedge fund pick high mgmt interest in top10 hfs
Analysed
B

ZNTL

Azenosertib (ZN-c3) monotherapy

Cyclin E1+ platinum-resistant ovarian cancer (DENALI Part 2)

YE 2026

rough period (placeholder)

0 delays

OK $352M market cap
big mover high mgmt interest
Screened
C

RGNX

ABBV-RGX-314 (subretinal)

Wet AMD (ATMOSPHERE/ASCENT)

Q4 2026

rough period (placeholder)

0 delays

SHORT $620M market cap
suspected mover high mgmt interest
Screened
C

BHVN

Opakalim (BHV-7000)

Focal epilepsy (RISE3)

H2 2026

rough period (placeholder)

2 delays

SHORT $2.03B market cap
high mgmt interest
Screened
C

MBRX

Annamycin + cytarabine

R/R AML (MIRACLE Part A)

December 2026-February 2027

only the month given

3 delays

SHORT $2M market cap
—
Analysed
C

ABOS

Sabirnetug (ACU193)

Early Alzheimer's disease (ALTITUDE-AD)

Late 2026

rough period (placeholder)

0 delays

EXPIRED $165M market cap
—
Screened
C

ACRS

Bosakitug (ATI-045)

Atopic dermatitis (Ph2)

Q4 2026

rough period (placeholder)

0 delays

EXPIRED $888M market cap
suspected mover hedge fund pick in top10 hfs
Screened
C

ATAI

VLS-01 (buccal DMT)

Treatment-resistant depression (Elumina)

Q4 2026

rough period (placeholder)

1 delay

EXPIRED $2.66B market cap
high mgmt interest
Screened
C

ATOS

(Z)-Endoxifen

Metastatic breast cancer

2026

rough period (placeholder)

0 delays

TIGHT $24M market cap
in no hfs
Screened
C

AURA

Belzupacap Sarotalocan (bel-sar)

Metastases to the choroid

2026 (est)

rough period (placeholder)

0 delays

SHORT $799M market cap
—
Screened
C

BHVN

Taldefgrobep alfa (BHV-2000)

Obesity

H2 2026

rough period (placeholder)

0 delays

EXPIRED $2.17B market cap
—
Screened
C

BIOA

BGE-102

Obesity (cardiovascular-risk POC)

H2 2026

rough period (placeholder)

0 delays

EXPIRED $517M market cap
—
Screened
C

BLRX

Motixafortide (BL-8040) + cemiplimab

Pancreatic cancer (CheMo4METPANC)

2026

rough period (placeholder)

0 delays

EXPIRED $12M market cap
in no hfs
Screened
C

CRIS

Emavusertib (CA-4948)

Chronic lymphocytic leukemia (TakeAim CLL)

December 2026

only the month given

0 delays

EXPIRED $8.9M market cap
—
Screened
C

FBRX

FB102

Celiac disease

2026

rough period (placeholder)

0 delays

TIGHT $1.57B market cap
big mover high mgmt interest
Screened
C

LTRN

LP-300

EGFR Exon-21 L858R NSCLC (HARMONIC)

H2 2026

rough period (placeholder)

0 delays

EXPIRED $36M market cap
in no hfs
Screened
C

OGEN

ONP-002

Traumatic brain injury (Ph2a, Australia)

YE 2026

rough period (placeholder)

1 delay

SHORT $2.4M market cap
in no hfs
Screened
C

ONCY

Pelareorep + bevacizumab + FOLFIRI

2L KRAS-mutant MSS metastatic colorectal cancer

Q4 2026

rough period (placeholder)

0 delays

EXPIRED $95M market cap
in no hfs
Screened
C

PTN

Bremelanotide + PDE5i

Erectile dysfunction

H2 2026

rough period (placeholder)

0 delays

EXPIRED $14M market cap
—
Screened
D

XFOR

Mavorixafor

Chronic/severe congenital neutropenia (4WARD)

H2 2026

rough period (placeholder)

1 delay

OK $375M market cap
—
Screened
D

MDWD

EscharEx

Venous leg ulcers (VALUE)

Q4 2026

rough period (placeholder)

0 delays

OK $181M market cap
high mgmt interest
Screened
D

RFL

Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin)

Niemann-Pick C1 (TransportNPC)

H2 2026

rough period (placeholder)

0 delays

OK $100M market cap
high mgmt interest
Screened
D

MDNAF

MDNA55 (bizaxofusp)

Recurrent glioblastoma (Ph2b)

Q4 2026

rough period (placeholder)

0 delays

EXPIRED $25M market cap
in no hfs
Screened
D

SKYE

Nimacimab

Obesity (CBeyond Part C)

Q4 2026

rough period (placeholder)

1 delay

EXPIRED $20M market cap
—
Screened
A

CGTX

Zervimesine (CT1812)

Alzheimer's disease (SHINE registrational read-through)

2027

rough period (placeholder)

0 delays

OK $95M market cap
in no hfs
Screened
A

AVIR

Bemnifosbuvir + ruzasvir

Hepatitis C (C-FORWARD)

Early 2027

rough period (placeholder)

1 delay

OK $376M market cap
suspected mover high mgmt interest
Screened
A

TECX

TX45

Pulmonary hypertension in HFpEF (APEX)

Early Q1 2027

rough period (placeholder)

1 delay

OK $558M market cap
suspected mover high mgmt interest
Screened
A

LXRX

ZYNQUISTA (sotagliflozin)

Hypertrophic cardiomyopathy (SONATA-HCM)

Q1 2027

rough period (placeholder)

0 delays

OK $1.03B market cap
—
Screened
A

ATXS

Navenibart (STAR-0215)

Hereditary angioedema (ALPHA-ORBIT)

Early 2027

rough period (placeholder)

0 delays

OK $718M market cap
high mgmt interest
Screened
A

COYA

COYA 302

ALS (ALSTARS)

Q1 2027

rough period (placeholder)

0 delays

OK $107M market cap
—
Screened
B

TYRA

Dabogratinib (TYRA-300)

Pediatric achondroplasia (BEACH301)

End Of Q1 2027

rough period (placeholder)

1 delay

OK $1.53B market cap
in top10 hfs
Screened
C

ANVS

Buntanetap (ANVS401)

Early Alzheimer's disease

Q1 2027

rough period (placeholder)

0 delays

SHORT $74M market cap
—
Screened
C

PSTV

REYOBIQ

Glioblastoma (ReSPECT-GBM)

Q1 2027

rough period (placeholder)

0 delays

EXPIRED $27M market cap
in no hfs
Screened
C

QNCX

Rapamycin/Sirolimus (LAM-001)

Bronchiolitis obliterans syndrome

Q1 2027

rough period (placeholder)

0 delays

EXPIRED $28M market cap
—
Screened
D

REPL

RP2 + Opdivo

Uveal melanoma (REVEAL)

Q1 2027

rough period (placeholder)

0 delays

OK $941M market cap
—
Screened
D

QNCX

Sirolimus/Rapamycin (LAM-001)

Bronchiolitis obliterans syndrome (duplicate BPIQ row)

Q1 2027

rough period (placeholder)

0 delays

EXPIRED $28M market cap
—
Screened
A

VOR

Telitacicept

Myasthenia gravis (UPSTREAM MG)

H1 2027

rough period (placeholder)

0 delays

OK $1.15B market cap
high mgmt interest
Screened
A

NBTX

NBTXR3 (JNJ-1900) +/- cetuximab

Head and neck cancer (NANORAY-312)

H1 2027

rough period (placeholder)

0 delays

N/A $1.95B market cap
—
Screened
A

ADAG

Muzastotug (ADG126) + Keytruda

Advanced MSS colorectal cancer

H1 2027

rough period (placeholder)

0 delays

N/A $279M market cap
in no hfs
Screened
A

ANRO

ALTO-300

Adjunctive major depressive disorder

H1 2027

rough period (placeholder)

1 delay

OK $999M market cap
—
Screened
A

KROS

KER-065 (rinvatercept)

Duchenne muscular dystrophy

H1 2027

rough period (placeholder)

0 delays

OK $198M market cap
—
Screened
A

MGTX

AAV2-hAQP1

Radiation-induced xerostomia (AQUAx2)

Q2 2027

rough period (placeholder)

0 delays

N/A $1.16B market cap
—
Screened
A

SPTX

GlyphAllo (SPT-300)

Major depressive disorder (BUOY-1)

H1 2027

rough period (placeholder)

0 delays

OK $1.2B market cap
in no hfs
Screened
A

TARS

TP-05

Lyme disease prevention (Calliope)

H1 2027

rough period (placeholder)

0 delays

OK $2.67B market cap
—
Screened
A

TARS

TP-04

Ocular rosacea

H1 2027

rough period (placeholder)

1 delay

OK $2.67B market cap
—
Screened
A

ZURA

Tibulizumab (ZB-106)

Systemic sclerosis (TibuSURE)

H1 2027

rough period (placeholder)

0 delays

OK $535M market cap
—
Screened
B

HRMY

EPX-100 (clemizole)

Dravet syndrome (ARGUS)

H1 2027

rough period (placeholder)

1 delay

N/A $2.04B market cap
—
Screened
B

HRMY

EPX-100 (clemizole)

Lennox-Gastaut syndrome (LIGHTHOUSE)

H1 2027

rough period (placeholder)

1 delay

N/A $2.04B market cap
—
Analysed
B

RARE

DTX301

OTC deficiency (Enh3ance 64-week)

H1 2027

rough period (placeholder)

0 delays

SHORT $2.45B market cap
—
Screened
B

PRTA

BMS-986446 (PRX005)

Early Alzheimer's disease (TargetTau-1)

H1 2027

rough period (placeholder)

0 delays

N/A $444M market cap
—
Screened
B

RXRX

REC-4881

Cancer (LILAC, biomarker-selected)

H1 2027

rough period (placeholder)

0 delays

OK $1.68B market cap
—
Screened
C

PROK

Rilparencel (REACT)

Diabetic CKD (PROACT-1)

Q2 2027

rough period (placeholder)

0 delays

TIGHT $465M market cap
high mgmt interest
Screened
C

ADVM

Ixo-vec (ADVM-022)

Wet AMD (ARTEMIS)

H1 2027

rough period (placeholder)

0 delays

EXPIRED $96M market cap
—
Screened
C

ENLV

Allocetra

Knee osteoarthritis (Ph2b)

Q2 2027

rough period (placeholder)

0 delays

EXPIRED $37M market cap
in no hfs
Screened
C

JUNS

JOTROL (resveratrol)

Parkinson's disease (RESET)

H1 2027

rough period (placeholder)

0 delays

EXPIRED $4.4M market cap
in no hfs
Screened
C

KARD

Ataciguat

Moderate calcific aortic valve stenosis (KATALYST-AV)

H1 2027

rough period (placeholder)

0 delays

SHORT $1.81B market cap
in no hfs
Screened
C

KARD

Tonlamarsen

Acute severe hypertension / post-hospitalization BP

H1 2027

rough period (placeholder)

0 delays

SHORT $1.81B market cap
in no hfs
Screened
C

KARD

Danicamtiv

Genetic/familial dilated cardiomyopathy (KINSHIP-DCM)

H1 2027

rough period (placeholder)

0 delays

SHORT $1.81B market cap
in no hfs
Screened
D

MGNX

Lorigerlimab monotherapy

Platinum-resistant ovarian / clear-cell gynecologic cancer (LINNET)

H1 2027

rough period (placeholder)

1 delay

EXPIRED $248M market cap
—

Want to see what happened to candidates that have left this board? See the archive →

Screen provenance

For each screening run: the filters used, the set of companies searched, known data errors and missing data. This is for checking our work, not for ranking.

Run 2026-08-11 catalyst dates 2026-08 to 2026-09▾

Screening only, per framework/06-prompts.md § Triage and framework/02-connectors.md § Triage pass. No claim here may enter an analysis without being re-verified there.

Companies searched

companies at or below 3b: 572 calendar rows pulled: 828 in window any stage event: 81 in window phase2 family prefilter ids: 22 ids resolved to a ticker: 22 ids excluded above cap: 5 tickers surviving cap with qualifying id: 16 tickers with authoritative drug rows fetched: 16 qualifying program rows: 17 combined phase rows excluded on stage: 8

Filters used

market capitalisation <= $3,000,000,000 USD; catalyst is a Phase 2 data readout; window 2026-08 to 2026-09, effective 2026-08-11 through 2026-09-30 (a catalyst already past does not qualify)

Missing data

  • fetch_all_upcoming_catalysts was used as the stage-and-date pre-filter over drug ids per 02-connectors.md § Triage pass step 2. It terminated NATURALLY at 828 unique rows (last page returned 78 of a possible 250, and offset 1000 returned empty) rather than at a page cap, so it is treated as complete for this run. fetch_company_drugs was called only on the 16 tickers this pre-filter surfaced, never on all 572 tickers under the cap, so a qualifying Phase 2 readout at a company never named as furthest_drug/next_drug_catalyst/next_bigmover_drug_catalyst by ANY id in the 828-row feed would not have been reached at all. This run did not surface a case of that (unlike 2026-08-07's KARD case, which found an extra qualifying row within an already-resolved ticker), but that is not proof none exists -- it is a structural blind spot of the method, not a property of this particular universe.
  • The stage_label filter was drawn narrowly, matching the 2026-08-07 precedent: only 'Phase 2', 'Phase 2a' and 'Phase 2b' were kept as 'Phase 2 data readout'. Combined-phase 'Phase 1/2' and 'Phase 2/3' trials were excluded even where event_label was 'Data readout' and the date sat inside the window. All 8 such rows are logged in excluded (exhaustive for this window, not a sample). A caller who intended those to count would need a re-run with a broader stage_label list; step_6 in method quantifies how much the ranked count moves under a narrower reading in the other direction.
  • No market-cap floor was applied, since the caller specified none. Rows below include micro-caps under $30M (ALZN $6.6M, BIVI $7.5M, LGVN $24.2M, CNSY $26.4M).
  • Triage does not call CT.gov, PubMed, Open Targets, ChEMBL or web search. Every catalyst date, enrollment figure and safety note below is BPIQ's own, read only against the note field in the same record -- none of it is independently verified and none of it is citable in an analysis without being re-checked there.
  • 'slips' was counted qualitatively from reading each company's note changelog during the per-ticker sweep, the same method the 2026-08-04 and 2026-08-07 screens used, rather than a mechanical string-diff. A second reviewer could reasonably differ by one slip on a row where a narrowing (a quarter or season specified down to an exact day, or vice-versa) is arguably a specification rather than a genuine change; flagged in the row's own comment where it mattered (CNSY, TLSA, IRON).
  • The caller-reported website figure of 12 companies for this same filter could not be reproduced exactly from data available to this run. The closest reconciliation found is 11 companies under a strict stage_label=='Phase 2' reading (one short of 12, see method step_6); the excluded list below carries every candidate explanation checked -- the four above-cap companies, the one just-above-cap company (ALMS), the eight combined-phase rows, the one just-outside-window company (SXTP), and the one label/date-conflict row (BIVI) -- so the orchestrator can test other combinations without re-running the sweep.

Data errors seen in the data connectors

  • fetch_all_upcoming_catalysts ignored start_date/end_date exactly as 02-connectors.md documents (neither was passed this run, since passing them was already known to be pointless): the feed's first page began at catalyst_date 2026-08-10, one day before this run's own window start, and rows ascend monotonically by catalyst_date through 2029-12-31 before a 78-row null-catalyst_date tail closes the feed at 828 total rows.
  • catalyst_date is synthesized from period text on the large majority of qualifying rows (e.g. 'Mid-2026' -> 2026-08-15, 'Q3 2026' -> 2026-09-30, 'Summer 2026' -> 2026-08-31, 'Late Summer 2026' -> 2026-08-31). Only 1 of 17 qualifying rows (CNSY 15204, 'August 13, 2026') names an exact day.
  • The company screener's furthest_drug/next_drug_catalyst/next_bigmover_drug_catalyst id-join fields missed 6 of the pre-filter's 22 ids outright: the four above-cap companies (resolved anyway via catalyst_source, so cost nothing here) plus CNTB's second qualifying row. Every ticker this run actually needed was still reachable, but only because the catalyst_source URL fallback worked on all 6 -- a row whose catalyst_source were also blank or unparseable (as 17051/CHRS's was, until the id-join itself resolved it) would have been lost entirely.
  • Two rows describing what reads as the same underlying event -- argenx's efgartigimod/VYVGART myositis data -- are filed under two different companies: ARGX (id 18163, the originator) and ZLAB (id 20688, Zai Lab, argenx's China-market partner). Both fall outside this screen on stage grounds (Phase 2/3) so it did not need resolving here, but it is the 'one row can cover two things' bug the corpus already tracks, on a cross-company axis rather than within one company.
  • BioVie's SUNRISE-PD (Bezisterim, early Parkinson's, id 17384): the note reports its own topline result directly ('08/06/26:- SUNRISE-PD topline Ph2b results reported; met endpoints') while stage_event_label still reads 'Phase 2b Update' rather than 'Data readout', has_catalyst remains true, and catalyst_date/catalyst_date_text are null/'TBA'. The structured fields never caught up to the event the note already describes. Logged in excluded.
  • Rein Therapeutics (RNTX, id 18014): the company-tier cash_runway_end_date (2026-07-25, already in the past as of this 2026-08-11 run) directly contradicts the program-tier note's own more recent claim (05/18/26) that 'Financing closed; expects to fund RENEW Ph2 through completion; cash runway into Q1 2028.' Neither field was updated to match the other as of this run; flagged rather than resolved.

Left out

  • ARGX (17511) — Empasiprubart — argenx is far above the $3B cap ($53.79B); resolved via catalyst_source URL company name, not the id-join fields.
  • ACAD (17283) — ACP-204 — ACADIA Pharmaceuticals is above the $3B cap ($5.03B); resolved via catalyst_source URL company name.
  • SYRE (18848) — SPY003 — Spyre Therapeutics is above the $3B cap ($9.25B); resolved via catalyst_source URL company name.
  • SYRE (19043) — SPY072 (SPY002-072) — Same company and cap reason as SPY003 above -- Spyre's second qualifying id in this window.
  • ALMS (18878) — ESK-001 — Alumis is just above the $3B cap ($3.52B, ~17% over) -- the closest above-cap near-miss found in this screen; no company anywhere sits between $3.0B and $3.1B (checked directly).
  • CHRS (17051) — Toripalimab +/- CHS-006 (anti-TIGIT) — stage_label is 'Phase 1/2', excluded by this run's narrow reading of 'Phase 2 data readout'. Coherus is well within the cap ($196M).
  • AURA (17079) — Belzupacap Sarotalocan (Bel-sar / AU-011) — stage_label is 'Phase 1/2', same narrow-reading exclusion ($826M market cap).
  • CLRB (18881) — CLR 121125 — stage_label is 'Phase 1/2', same narrow-reading exclusion.
  • CLRB (19077) — CLR 125 — stage_label is 'Phase 1/2', same narrow-reading exclusion -- Cellectar's second qualifying id in this window.
  • BEAM (18113) — BEAM-302 — stage_label is 'Phase 1/2' (first patient just dosed in the 'global pivotal cohort' per the 08/04/26 release), same narrow-reading exclusion. Day-precise date; market cap close to the cap at $2.84B.
  • OCGN (17593) — OCU410ST — stage_label is 'Phase 2/3', same narrow-reading exclusion.
  • ARGX (18163) — Efgartigimod (myositis) — stage_label is 'Phase 2/3'; also above the cap on its own (see the Empasiprubart row above) -- excluded on both grounds.
  • ZLAB (20688) — VYVGART/Efgartigimod Alfa (myositis) — stage_label is 'Phase 2/3', same narrow-reading exclusion. Zai Lab is the China-market partner filing what reads as the same underlying efgartigimod myositis data as argenx's row above ($2.62B, close to the cap).
  • SXTP (17696) — Arakoda (Tafenoquine) -- Babesiosis — Interim babesiosis data guided for October 6, 2026 -- 6 days after this window's 2026-09-30 close, the closest date-based near-miss found in this screen. Also carries an EXPIRED cash_runway_end_date (2026-07-18, already past this run's own date) on cash of $3.3M.
  • BIVI (17384) — Bezisterim (NE3107) -- SUNRISE-PD, early Parkinson's — has_catalyst:true with no catalyst_date, but the note reports topline results already delivered 08/06/26 ('met endpoints'); stage_event_label still reads 'Phase 2b Update', not 'Data readout', so it fails both the date test and the event-label test. A screener reading note text rather than structured fields could plausibly still count this one.

Legend

precision:
DAY = catalyst_date_text names a day. MONTH = names a month or a season (Summer/Fall/Winter/Spring), per the schema's own wording -- 'Summer 2026' and 'Late Summer 2026' are both classified MONTH here, distinct from a quarter or half modified the same way ('Late Q3 2026' stays PERIOD). PERIOD = half, quarter or year only (including one modified by early/late/mid); catalyst_date is synthesized by BPIQ. UNKNOWN = no date disclosed at all.
slips:
Count of distinct changes to the guided timing visible in the note changelog actually read during this sweep, including narrowings/specifications as well as delays, and one deliberate pull-in (IRON, 'moved up to Q3 2026'). 0 means the guidance was stable, or only seen once, across the updates read -- not that no changelog exists. A second reviewer could differ by one on rows flagged in their own comment.
runway_vs_catalyst:
EXPIRED = cash_runway_end_date is more than ~1 month before this row's own catalyst_date. Four rows carry a cash_runway_end_date already before the 2026-08-11 run date itself: OSTX, ALZN and the excluded near-miss SXTP genuinely so; RNTX's field also reads EXPIRED but its own note directly contradicts it (see comment and connector_bugs_observed). SHORT = up to ~1 month before. TIGHT = within ~1 month after (BIVI, 5 days). OK = comfortably after. N/A = null or a far-future sentinel (year >= 2100).
tier:
A = clean, funded (OK/N/A runway), materially binary for the company reading it out, no specific red flag surfaced in the sweep. B = a real readout but diluted materiality: a correlated sister program at the same company already counted elsewhere in this table (CNTB's second row), or the readout itself is a conference poster of 'emerging'/interim data rather than a definitive powered topline (CNSY). C = runway_vs_catalyst reads EXPIRED, SHORT or TIGHT -- a financing event is plausible before or around the date (BIVI, OSTX, ALZN, CUE). D = a specific negative signal surfaced in the note itself -- here, RNTX alone, which stacks a prior partial clinical hold, a catalyst_date_text/note date conflict ('Q3 2026' vs the note's own 'H2 2026'), and a runway figure its own note directly contradicts.
Run 2026-08-07 catalyst dates 2026-10 to 2027-06▾

Screening only, per framework/06-prompts.md § Triage and framework/02-connectors.md § Triage pass. No claim here may enter an analysis without being re-verified there.

Companies searched

companies at or below 3b: 570 calendar rows pulled: 788 in window phase2 family readouts market wide: 117 ids resolved to a ticker: 90 ids excluded above cap or unlisted: 27 tickers surviving market cap cut with a qualifying id: 75 tickers with authoritative drug rows fetched: 75 qualifying program rows: 95

Filters used

market cap max $3B; stage/event: Phase 2 data readout

Missing data

  • fetch_all_upcoming_catalysts was used as the stage-and-date pre-filter over drug ids per 02-connectors.md § Triage pass step 2. The feed terminated NATURALLY at 788 unique rows (offset 1000 and 1250 both returned empty) rather than at a page cap, so it is treated as complete for this run -- but this is an inference from two empty pages, not a documented guarantee, and a qualifying Phase 2 readout entirely absent from this calendar feed would not have been reachable by the id-join path in step 3. The KARD/Danicamtiv near-miss (see connector_bugs_observed) shows this blind spot is not merely theoretical even when the company itself was correctly identified via its sibling programs.
  • The stage_label filter was drawn narrowly: only 'Phase 2', 'Phase 2a' and 'Phase 2b' were kept as 'Phase 2 data readout' per the caller's filter. Combined-phase trials labelled 'Phase 1/2' or 'Phase 2/3' were excluded even where their event_label was 'Data readout' and the date sat inside the window (examples logged in 'excluded' below). A caller who intended those combined-phase trials to count would need a re-run with a broader stage_label list.
  • No market-cap floor was applied, since the caller specified none. Rows below include micro-caps under $10M (CRIS at $8.9M, JUNS at $4.4M, SXTP at $3.2M, OGEN at $2.4M).
  • Triage does not call CT.gov, PubMed, Open Targets, ChEMBL or web search. Every catalyst date, enrollment figure and safety note below is BPIQ's own, read only against the note field in the same record -- none of it is independently verified and none of it is citable in an analysis without being re-checked there.
  • 'slips' was counted qualitatively from reading each company's note changelog during the per-ticker sweep, the same method the 2026-08-04 Phase 3 screen used, rather than a mechanical string-diff. A second reviewer counting the same note text could reasonably differ by one slip on a handful of rows; 0 is reported wherever the guided date was not observed to change across the updates actually read.

Data errors seen in the data connectors

  • fetch_all_upcoming_catalysts ignored start_date/end_date exactly as 02-connectors.md documents: requested 2026-10-01..2027-06-30, the first page returned rows starting 2026-08-13, ascending by catalyst_date from a fixed point that includes already-past-dated rows near the front and a long null-catalyst_date tail at the end. Paged and filtered client-side throughout.
  • fetch_all_upcoming_catalysts returns no ticker and no market cap on any row, so it cannot screen companies -- used only as a stage/date id pre-filter, exactly as prescribed.
  • catalyst_date is synthesized from period text on the large majority of qualifying rows (e.g. 'H2 2026' -> 2026-12-31, 'Late 2026' -> 2026-12-31, 'Early Q4 2026' -> 2026-11-15, 'Mid-2027' -> 2027-08-15, 'Early Q1 2027' -> 2027-02-15). Only 8 of 95 rows name a day or a specific month in catalyst_date_text; all others carry PERIOD precision and the synthesized date should not be read as a real commitment.
  • A single BPIQ drug id can be missing from a company's own furthest_drug/next_drug_catalyst/next_bigmover_drug_catalyst join fields even when its sibling programs at the same company DO join correctly: Kardigan (KARD) drug id 20587 (Danicamtiv) did not resolve via the direct id join, and was only recovered because fetch_company_drugs was called on KARD anyway for its two sibling qualifying programs (20585, 20586). A ticker resolved for any reason should always have fetch_company_drugs called on it in full, not just for the specific id that triggered the resolution.
  • Two BPIQ drug ids (20409 and 20413, both 'Rapamycin/Sirolimus (LAM-001)' in bronchiolitis obliterans syndrome at QNCX) describe the same trial, same catalyst_date, same catalyst_date_text -- a duplicate-row pattern distinct from the documented 'one row can cover two genuinely different trials' bug. Both are kept in 'ranked' per the output rule (every row from fetch_company_drugs is published), with the duplicate flagged in its own comment and given tier D so it is not read as an independent second event.
  • cash_runway_end_date carries far-future sentinel-pattern values beyond the documented 2126-03 case: 2125-06 (IMAB), 2049-10 (PHAT), 2045-11 (KROS), 2041-06 (FGEN), 2035-03 (RAPP), 2030-07 (PHAR), 2030-11 (SNSE), 2029-05 (NKTR), 2028-xx (several). Only years >= 2100 were treated as the not-applicable sentinel here, consistent with 02-connectors.md's stated 2126-03 example; the 2028-2049 values were treated as genuine (if perhaps optimistic) runway figures, not sentinels, since no documented bug covers that range and second-guessing them would be a guess, not a finding.

Left out

  • IDYA (16776) — Darovasertib — IDEAYA Biosciences is above the $3B cap (not in the 570-ticker universe); resolved via catalyst_source URL company name.
  • DNTH (19223) — Claseprubart (DNTH103) — Dianthus Therapeutics is above the $3B cap.
  • TEVA (18444) — Emrusolmin / TEV-286 — Teva is a mega-cap, far above the $3B cap.
  • N/A (20587) — Danicamtiv (KINSHIP-DCM) -- initial pass only — catalyst_source was a raw SEC EDGAR S-1/A filing URL with no company name to parse; treated as an unresolved pre-IPO filer in step 3, then recovered in step 4 once ticker KARD was known from its two sibling Kardigan programs and included in 'ranked' -- kept here only to document the method's initial miss.
  • ALKS (18685) — ALKS 2680 (RDC-264177) — Alkermes is above the $3B cap.
  • N/A (20545) — Velinotamig (BCMAxCD3) -- Autoimmune Cytopenias — stage_label is 'Phase 1/2', a combined-phase trial excluded by this run's narrow reading of 'Phase 2 data readout' (see coverage_gaps).

Legend

precision:
DAY = catalyst_date_text names a day. MONTH = names a month or season. PERIOD = half, quarter or year only (including a quarter modified by 'early'/'late'/'mid'); catalyst_date is synthesized by BPIQ.
slips:
Count of distinct changes to the guided timing visible in the note changelog actually read during this sweep. 0 means the guidance was stable across the updates read, not that no changelog exists.
runway_vs_catalyst:
EXPIRED = cash_runway_end_date is more than ~1 month before the catalyst. SHORT = up to ~1 month before. TIGHT = within ~1 month after. OK = comfortably after. N/A = null or a far-future sentinel (year >= 2100, extending the documented 2126-03 example).
tier:
A = clean, funded, materially binary for the company reading it out, no specific red flag surfaced in the sweep. B = a real readout but diluted materiality: multi-asset company (>10 assets), a correlated/sister program at the same company already counted elsewhere in this table, an investigator-initiated or partner-run trial, or a label-expansion trial on an already-approved, revenue-generating product. C = cash_runway_end_date falls at or before the catalyst per runway_vs_catalyst (EXPIRED/SHORT/TIGHT) -- a financing event is plausible before or around the date. D = a specific negative signal surfaced in the note itself (a missed prior endpoint, a discontinued cohort, a partial clinical hold, funding contingent on finding a partner) or the row is a literal duplicate of another row in this table.
Run 2026-08-04 catalyst dates 2026-10 to 2027-06▾

Screening only, per framework/06-prompts.md § Triage and framework/02-connectors.md § Triage pass. No claim here may enter an analysis without being re-verified there.

Companies searched

companies at or below 3b: 572 calendar rows pulled: 750 calendar rows in window: 459 in window phase3 readouts market wide: 82 tickers surviving market cap cut: 47 tickers with authoritative drug rows: 47 qualifying program rows: 51

Filters used

market cap max $3B, Phase 3 data readout

Missing data

  • A Phase 3 readout inside the window that is absent from the fetch_all_upcoming_catalysts feed would not be reachable by this method. The feed terminated naturally at 750 rows rather than at a page cap, so it is treated as complete, but this is an assumption, not a verified fact.
  • No market-cap floor was applied, since the caller specified none. Rows below include a $2M shell (MBRX).
  • Triage does not call CT.gov, PubMed, Open Targets, ChEMBL or web search. Every catalyst date below is BPIQ's own, cross-checked only against the note field in the same record.

Data errors seen in the data connectors

  • fetch_all_upcoming_catalysts ignored start_date/end_date: requested 2026-10-01..2027-06-30, first page returned rows from 2026-07-31. Confirms 02-connectors.md. Paged and filtered client-side.
  • fetch_all_upcoming_catalysts returns no ticker and no market cap, so it cannot screen companies. Used only as a stage/date filter over drug ids.
  • catalyst_date is synthesized from period text on 44 of 51 qualifying rows (e.g. 'H2 2026' -> 2026-12-31, 'H1 2027' -> 2027-06-30, 'Early 2027' -> 2027-02-15). Only CMPX 17398 names a day.
  • cash_runway_end_date returns a 2126-03 sentinel for VTVT, XOMA, HRMY and PCRX. Treated as not-applicable, not as a 100-year runway.
  • BPIQ ticker RNA is Atrium Therapeutics, not Avidity Biosciences. Avidity (del-desiran, drug id 15268) is above $3B and is out of scope.
  • The BPIQ MCP server disconnected mid-sweep and reconnected; the 7 tickers outstanding at that point (CGEM, HRMY, BHVN, VNDA, RARE, PCRX, HCM) were fetched after reconnect. No row below is unverified.

Left out

  • ETNB (13548) — pegozafermin in MASH — Acquired by Roche 2025-10-30 per the row's own note. No independent equity to trade.

Legend

precision:
DAY = catalyst_date_text names a day. MONTH = names a month or season. PERIOD = half, quarter or year only; catalyst_date is synthesized.
slips:
Count of distinct changes to the guided timing visible in the note changelog. 0 means the same guidance was repeated unchanged.
runway_vs_catalyst:
EXPIRED / SHORT = cash_runway_end_date falls before the catalyst. TIGHT = within ~1 month after. OK = comfortably after. N/A = null or the 2126-03 sentinel.
tier:
A = pivotal binary for this company, credible date, funded through the readout. B = real readout but diluted materiality (partner-run, multi-asset, or revenue-generating). C = financing forces a raise at or before the event. D = the row's date label conflicts with its own note; likely not a readout in this window.